Fig. 4: IRF1/NLRC5 is required for ATM inhibition-induced expression of MHC-I.
From: ATM inhibition enhance immunotherapy by activating STING signaling and augmenting MHC Class I
A–C Vector control and ATM-KO CT26 cells were transfected with siRNA-Ctrl or siRNA-IRF1 for 48 h. Surface expression of H2Kd/H2Dd was determined by flow cytometry (A and B). qRT-PCR was used to measure the mRNA level of H2Kd/H2Dd, IRF1 and NLRC5 (C). D–F Vector control and ATM-KO CT26 cells were transfected with siRNA-Ctrl or siRNA-NLRC5 for 48 h. Surface expression of H2Kd/H2Dd was determined by flow cytometry (D and E). qRT-PCR was used to measure the mRNA level of H2Kd/H2Dd, IRF1 and NLRC5 (F). G–J Vector control and ATM-KO CT26 cells were transfected with shRNA-Ctrl or shRNA-STING. Surface expression of H2Kd/H2Dd was determined by flow cytometry (G and H). STING expression was determined by Immunoblots (I). IFNβ and CXCL10 expression were determined by qRT-PCR (J). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
